Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABBV-668 in moderate to severe ulcerative colitis
NCT05570006Phase 2Completed
- Sponsor
- AbbVie Inc.
- Start
- Mar 2023
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 2, open-label, single-arm trial of ABBV-668 in ulcerative colitis (UC), sponsored by AbbVie Inc. Primary endpoints: Endoscopic Improvement at 8 weeks and Adverse Events. Started Mar 2023; status: completed.
02
Drugs
ABBV-668
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT05570006.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05570006.